Valneva Stock in 2026: Share Price, Vaccines and Analysis

Valneva stock (ticker VLA, Euronext Paris, ISIN FR0004056851) is the most talked-about — and one of the riskiest — French biotechs on the market: as of October 23, 2026, the shares trade at around €2.40, down nearly 43% over one year and 88% over five years, while the analyst consensus shows a median target of €5.37 — a theoretical upside of more than 128%.

This dizzying gap between the share price and the target sums up the Valneva paradox: a company that developed the world’s first chikungunya vaccine, approved by the major agencies — yet whose stock is going through a regulatory storm, with the United Kingdom having just withdrawn its authorization for the IXCHIQ vaccine. Between medical hope and stock market reality, this profile covers the whole case: share price, products, history, consensus, risks — and the central question: should you buy Valneva stock, or simply keep an eye on it?

Valneva Live Share Price

Valneva trades on Euronext Paris, in euros, among small-cap healthcare stocks. The stock is PEA-eligible — a plus for French savers — but its liquidity is that of a biotech: daily volumes are modest, bid-ask spreads are wider than on large caps, and limit orders are a must to avoid unfortunate fills.

Recent figures illustrate the stock’s volatility: +0.04% in the last session — the stock stuck around €2.40 —, -15.25% over one month since the UK regulatory shock, -1.42% over six months and -42.83% over one year. Longer windows show the scale of the historical decline: -54.56% over three years and -88.11% over five years. An investor who put €1,000 in five years ago now holds about a hundred euros.

Despite this track record, the consensus maintains a median target of €5.37 — more than double the share price. This setup, in which analysts remain overwhelmingly bullish on a collapsed stock, is typical of biotechs: valuation depends on binary regulatory events — approvals, withdrawals, trial results — that can send the stock soaring or plunging by tens of percent in a single session.

ISINFR0004056851
Exchange and tickerParis — VLA.PA
SectorHealthcare
Valneva SEVLA.PA · Paris
2,49 €-3,23 %
Clôture précédente2,57 €
Plus haut du jour2,51 €
Plus bas du jour2,44 €
Plus haut 52 semaines5,15 €
Plus bas 52 semaines2,03 €
Volume88 277
Capitalisation473 M
Rendement du dividende0,00 %
Objectif moyen des analystes6,20 €
Mis à jour le 2026-11-19 12:45:37 · Source : Yahoo · Données indicatives, ne constituent pas un conseil en investissement.

Yahoo Finance — data checked on Oct 23, 2026: price and fundamentals. Market data is indicative and does not constitute investment advice.

Among the other healthcare stocks covered on this site, Utah Medical stock and Vertex Pharma stock are also worth a look.

The UK Shock: Britain Withdraws IXCHIQ

The event dominating the stock’s news is clear-cut: the United Kingdom has withdrawn the marketing authorization for IXCHIQ, Valneva’s chikungunya vaccine. The decision hits the group’s flagship product just as its international rollout was beginning — and it comes on top of other regulatory setbacks the vaccine has faced this year in certain markets.

The market reacted without nuance: the stock lost 15% in a month. But analysts’ reading is more mixed: Stifel, in particular, reaffirmed its confidence in the stock despite the UK decision — pointing out that the authorization remains in place in key markets, including the United States and Europe, and that chikungunya is spreading geographically, with outbreaks now reaching North America and Southern Europe.

So the debate is open: is the UK withdrawal a bump in the road or the first sign of a deeper problem with the product?

For investors, this episode is a reminder of the sector’s golden rule: in a biotech, a vaccine approval is not a final event — it is a status that can be revoked, re-examined and challenged. Every agency decision can rewrite the investment thesis from scratch: this specific risk alone justifies the sector’s discount.

What Valneva Sells Today

Behind the IXCHIQ storm, the group has a real portfolio. Its historical product, IXIARO — a Japanese encephalitis vaccine given to travelers and military personnel — generates recurring revenue and an established distribution base in the US and European markets. On top of this come clinical programs: the Lyme disease vaccine, developed with Pfizer and in advanced trials — a potentially very large market in North America and Europe — as well as work on the Zika virus.

The business model of a biotech like Valneva therefore has two levels: a commercial level — IXIARO, royalties, partnerships — that funds the group’s running costs; and an options level — IXCHIQ, Lyme, Zika — on which the valuation benchmarks depend. The stock market mainly values the second level: that is where the analysts’ 128% upside lies… along with the risk of further setbacks.

History: A French Biotech Born from Mergers

Valneva was formed in 2013 through the merger of Vivalis — a French company specializing in stem cells and vaccine production — with the vaccines business of Austrian group Intercell. Its headquarters are in Saint-Herblain, near Nantes, with production sites in Lyon and Scotland — a European manufacturing footprint that is rare for a biotech of this size and allows it to make its own vaccines rather than outsourcing everything.

The stock’s path has tracked the decade’s vaccine hopes: steady gains up to the peaks of the Covid period, when markets discovered that vaccines could be a global business — then a long decline as the health-related euphoria faded and clinical milestones stretched out over time. The development of the Livingston manufacturing site in Scotland and the arrival of reference investors marked the way, without reversing the stock’s long downward slope. Moving the listing to Paris alone closed the Austrian chapter.

For shareholders, this history teaches patience — and humility: even real scientific successes, such as the world’s first approval of a chikungunya vaccine obtained in the United States, only turn into stock market value if commercialization follows. That is precisely the test the group is going through today.

Chikungunya: A Disease on the Move

Understanding IXCHIQ’s potential means understanding the disease. Chikungunya is a mosquito-borne virus — spread mainly by Aedes albopictus — known since the 1950s in Africa and Asia, and long seen as a distant tropical problem.

Those days are over: the tiger mosquito has settled permanently in Southern Europe and North America, and outbreaks keep coming — from the Caribbean to Brazil, from India to Réunion, and even locally acquired cases in mainland France and Italy. Although rarely fatal, the disease is debilitating: disabling joint pain that lasts for months, sometimes years.

This shifting geography is what creates the market: travelers, deployed military personnel, populations in endemic areas — and tomorrow, if the mosquito keeps spreading, public health demand in wealthy countries themselves. No other vaccine is currently approved against this disease: IXCHIQ holds a worldwide exclusivity that the UK withdrawal does not erase in other markets.

The commercial question is therefore one of pace: how quickly will health systems adopt vaccination — recommendations, reimbursement, campaigns? Every country that decides is a revenue milestone for Valneva and a test of the thesis for the stock.

The second level of the portfolio — Lyme disease — follows the same logic on a larger scale: hundreds of thousands of estimated cases every year in North America and Europe, no human vaccine available since the historical withdrawal of the previous product in the 2000s, and a development and commercialization partnership with Pfizer: if the trials succeed, the US drugmaker will put its global commercial firepower behind the vaccine.

This type of deal is what turns a biotech into a potential income stock — and what justifies, in the eyes of the consensus buyers, a target more than double the share price.

Tableau originalDiversifiez votre patrimoineInvestissez dans l’artDes tableaux originaux, pièces uniques signées par l’artiste. Un actif tangible, loin des écrans et des cotations.Voir les tableaux →

Analyst Consensus: An Extreme Divide

Coverage of the stock is limited — nine analysts — and their split is striking: 8 buys and 1 sell, with no middle ground. In other words, the optimists see a stock that could double or triple if IXCHIQ and Lyme deliver on their promise; the other camp believes the regulatory risks and cash burn justify selling, whatever the therapeutic potential.

This divide with no center — enthusiastic buyers against categorical sellers — should be a warning for individual investors: when professionals agree on nothing, your own analysis matters more than ever. The objective factors to track are well documented: agency decisions on IXCHIQ market by market, progress in the Lyme trials, the cash position and burn rate, and the group’s ability to sign partnerships that share the risk.

By comparison, a giant, defensive vaccine exposure exists on the French market: Sanofi stock, whose vaccines division is global and diversified — the exact opposite profile of Valneva’s concentration.

How to Buy Valneva Stock — with a Method

Technically, buying is simple: a standard securities account or a PEA with a Euronext broker, and above all a limit order — on a thinly traded stock, a market order can fill well beyond the last displayed price. Our guide on how to invest in the stock market explains the mechanics, and our comparison of reliable brokers compares the real fees.

Method matters more than mechanics. A position in Valneva follows option logic — the same reasoning we applied to Casino, now Plesio: a small slice of the portfolio, sized so that a total loss would not change your life, reassessed at every regulatory event. Anyone who does not accept this framework should not buy Valneva stock — whatever upside the consensus shows.

The Risks in the Valneva Case

Regulatory risk dominates: the UK withdrawal of IXCHIQ proves it — each market can rewrite the rules, and unfavorable decisions sometimes come one after another. Cash risk: a biotech burns cash between milestones; any additional fundraising through a share issue would further dilute shareholders who have already been heavily diluted in the past.

Clinical timeline risk: the Lyme trials move at their own pace — a delay pushes back revenue and tests the market’s patience. Finally, liquidity risk: thin volumes amplify moves in both directions — including on the way out, at the worst possible time.

On top of these comes the symmetrical risk: a major positive regulatory event — an approval in a large market, convincing clinical results — and the stock can double in a session, leaving the overly cautious investor behind. That is the whole difficulty of this case: the risk of losing a lot quickly, and the possibility of gaining a lot almost as fast.

Reading the Cash Position: A Biotech’s Real Counter

For a company like Valneva, one number matters more than any other: available cash and how fast it is eroding — the famous cash burn. A biotech without a major product in full rollout consumes cash every quarter: clinical trials, scientific salaries, manufacturing capacity, commercial preparations.

Investors therefore track two lines in the quarterly accounts: the net cash position on one hand and the average burn on the other — and from these, the group’s remaining runway in quarters. It is this simple arithmetic, more than any opinion, that signals fundraisings before they happen — and therefore dilution before it hits.

Three classic outcomes emerge when the runway shrinks: a dilutive fundraising, a partnership that shares costs in exchange for a share of future revenue, or a tie-up with a larger drugmaker. Each has different consequences for shareholders — from pure dilution to a takeover at a premium. Valneva stock has already been through these chapters: one more reason to read every release with the cash counter first and the vaccine thesis second — the order matters, because without the first, the second does not have time to play out.

Verdict: Should You Buy Valneva Stock in 2026?

The bull case: a product unique in the world — the first chikungunya vaccine —, major approvals still valid, a credible Lyme pipeline, European manufacturing facilities, and a consensus target at +128% maintained by eight out of nine analysts. The cautious case: a fresh and unresolved regulatory shock, cash that shrinks every quarter, past dilution, and a stock that has destroyed 88% of its value in five years — statistical proof that biotech potential is not always realized.

Our reading is straightforward: Valneva stock is not an investment — it is a controlled bet on binary events. It belongs only in the speculative part of a portfolio, in a small size, with a thesis written down in black and white — the milestones you expect and the date on which you will reassess — and the discipline to cut the position if a decisive milestone fails. For confident healthcare exposure, large diversified drugmakers remain the appropriate vehicle.

Valneva Stock FAQ

What is Valneva’s share price today?

As of October 23, 2026, the stock trades at around €2.40 on Euronext Paris. Over one month, it is down 15.25% after the UK withdrew the IXCHIQ authorization; over five years, the loss reaches 88%.

Why did the United Kingdom withdraw IXCHIQ’s authorization?

The UK decision was announced without the group publicly challenging its scientific basis. Valneva maintains that the US and European authorizations remain valid. The market is waiting for the next agency decisions to tell whether this was an accident or a structural signal.

Is Valneva stock eligible for a PEA?

Yes. Valneva is listed on Euronext Paris with a French ISIN: the shares can be bought in a standard securities account or a PEA, preferably with limit orders given the thin liquidity.

What is the analysts’ price target?

The median target of the nine analysts covering the stock is €5.37 — upside of more than 120% from the current share price. The split is radical: 8 buys versus 1 sell, with no intermediate recommendation.

What are the next milestones to watch?

Three main ones: regulatory decisions on IXCHIQ in other markets, trial results for the Lyme disease vaccine developed with Pfizer, and quarterly reports on the group’s cash and cash burn.

Is Valneva a stock for beginners?

No. The stock combines extreme volatility, binary regulatory risks, past dilution and thin liquidity: it requires regular monitoring and a real tolerance for heavy losses. Beginner investors should prefer diversified healthcare exposure.

What is the general view on Valneva stock?

The consensus on Valneva is sharply divided — buyers convinced by the pipeline versus sellers worried about cash — and this profile settles the question differently: through method. A stock that has lost 88% in five years, depends on binary regulatory events and pays no dividend should be treated as a bounded bet: a small speculative slice, written milestones, reassessment at every agency decision — the full details are in the sections above.

Is Valneva listed on the Nasdaq?

Valneva is listed primarily on Euronext Paris — the reference listing for a French investor, and PEA-eligible. The group also has a US listing in the form of American Depositary Shares (ADS) traded in the United States: both lines represent the same company, and the Paris line remains the simplest and most tax-efficient route for a French saver.

What is the stock’s exact listing?

The stock trades on Euronext Paris under the code VLA, ISIN FR0004056851 — the “Share Price” section of this profile gathers the full details and live tracking of the quote.

Conclusion: Between the Vaccine and the Bet

Valneva stock captures everything that fascinates and everything that worries about French biotechs: real medical innovation — the first vaccine against a spreading disease —, a book of clinical options, and a stock market track record that has punished poorly sized convictions. At €2.40 against a €5.37 consensus target, the analysts remain on the side of hope; the share price, for its part, reflects the caution of those who have already been burned.

So the answer to “should you buy?” is not a yes or a no — it is a method: a small position labeled speculative, written milestones, reassessment at every agency decision, and never more money committed than you are prepared to lose entirely. On that condition — and that condition alone — Valneva stock can find a place in a diversified portfolio in 2026.

Suivez-nous sur Telegram